| 9.13 -1.29 (-12.38%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.87 | 1-year : | 16.2 |
| Resists | First : | 11.88 | Second : | 13.87 |
| Pivot price | 7.56  |
|||
| Supports | First : | 7.62 |
Second : | 5 |
| MAs | MA(5) : | 9.42 |
MA(20) : | 7.29 |
| MA(100) : | 5.01 |
MA(250) : | 0 | |
| MACD | MACD : | 1 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 76.1 |
D(3) : | 84.4 |
| RSI | RSI(14): 64.5 |
|||
| 52-week | High : | 12.89 | Low : | 2.14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KLRS ] has closed below upper band by 27.0%. Bollinger Bands are 184.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.5 - 10.58 | 10.58 - 10.63 |
| Low: | 8.89 - 8.95 | 8.95 - 9 |
| Close: | 9.04 - 9.14 | 9.14 - 9.22 |
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Fri, 19 Dec 2025
Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts (KLRS) - Seeking Alpha
Fri, 19 Dec 2025
Kalaris Therapeutics raises $50M privately - MSN
Fri, 19 Dec 2025
Latham & Watkins Advises on Kalaris Therapeutics’ US$50 Million Private Placement - Legal Desire Media and Insights
Thu, 18 Dec 2025
Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth (KLRS) - Seeking Alpha
Thu, 18 Dec 2025
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing - TipRanks
Thu, 18 Dec 2025
Kalaris Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 12.5 (%) |
| Held by Institutions | 70.8 (%) |
| Shares Short | 399 (K) |
| Shares Short P.Month | 403 (K) |
| EPS | -38.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.24 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -63.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.24 |
| PEG Ratio | 0 |
| Price to Book value | 4.07 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|